This report was recently updated on November 17 2024 with the latest and most recent
market numbers
Global Neurological Biomarkers Market Size, Trends, and Analysis - Forecasts to 2026 By Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), By Type (Genomic, Proteomic, Metabolomic, Imaging, and Others), By End-User (Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations, and Others), By Region (North America, Europe, Asia Pacific, MEA, and CSA); Competitive Landscape, Company Market Share Analysis, and Competitor Analysis
Today, with advancing technology and neurological applications, biomarkers are getting importance in the market, and the researchers using these better and advanced technologies are able to keep track of brain health by studying these molecules called biomarkers. This awareness about the effectiveness of biomarker signature in diagnosing diseases, conditions, or disorders increases the effectiveness of treatments, enables professionals to diagnose diseases at an earlier stage, and quickly develops required drugs to deliver effective treatments. The beneficial features attributed to the neurological biomarkers and their early diagnosis enables the patients to experience early recovery and quicker response to the medications. These neurological biomarkers have made the brain a more accessible organ, thus enabling better treatments for neurological diseases and disorders.
The increasing prevalence of neurological diseases such as stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) necessitates accelerated medication growth. This is one of the key drivers driving demand development, as biomarkers aid in determining the effectiveness of novel medicines and clinical approaches. Another big growth-inducing trend is the growing use of minimally invasive surgeries and personalised drugs. Aside from that, since distinct neurological disorders possess common characteristics, there is an increased need for numerous biomarkers to distinguish diseases and their sub-types. Furthermore, advances in mass spectrometry and imaging procedures allow for the quicker assessment of a vast range of biochemical markers and structural improvements in the brain. This, including the advent of automated biomarkers and an increase in the volume of drug development, is expected to drive market growth.
Studies and research done by the United Nations organization have identified and shown that there are over 600 types of neurological disorders, which affect approximately over 1 billion people every year across the world. Every single individual out of six individuals in each corner of the world suffers from these disorders with various severity levels. Surveys have shown that approximately 6.8 million people witness death due to these neurological disorders. However, the health systems today across the globe are advancing and transforming in all sense, and their ability to diagnose neurological biomarkers is enabling them to decrease the increasing ratio of neurological disorders gradually. Also, these countries are investing ample funds in the medical sector, and the number of people interested in pursuing neurological studies is rising as well, thus increasing the availability of neurosurgeons globally and propelling growth in the neurological biomarkers market.
Depending on the application, the neurological biomarkers market is categorized as Alzheimer's disease, Parkinson's disease, multiple sclerosis, autism spectrum disorders, and others. Amongst these, Alzheimer's disease holds the largest share in the market. The advancing technological changes have enabled the professionals to identify multiple core biomarkers for Alzheimer’s disease-like total tau (T-tau), phosphorylated tau (P-tau), and amyloid-β (Aβ42), which essentially reflect the crucial elements of AD pathophysiology. These listed biomarkers evidently show the inclusion of Alzheimer’s disease even at the early stage. If these biomarkers show plaques or tangled structures with brain cells, it depicts that patient has Alzheimer's disease. This diagnosis has been tremendously undertaken for many decades due to the increasing geriatric population, family histories, down syndrome, cardiovascular disease, or even due to brain injuries leading to Alzheimer's disease.
Also, the application of neurological biomarkers in diagnosing Parkinson's disease is expected to grow at a faster rate within the market throughout the forecast period. The loss of different nerve cells and corresponding loss of chemicals like substantia nigra and dopamine indicate the inclusion of Parkinson's disease which is eventually becoming common.
Depending on the type, the neurological biomarkers market is categorized as genomic, proteomic, metabolomic, imaging, and others. Genomic type is substantially used to identify and diagnose biomarkers and subsequently identify various diseases and disorders, thus holding the market's largest share. Genomic techniques for diagnosing biomarkers facilitate precise understanding of the disease and enable the professionals and doctors to deliver medication treatment based on personalized diagnostic and individual or patient’s genetic components. Initially, these complex genetic components were difficult to be identified to detect the disorders like Alzheimer's or Parkinson's; however, these complexities have reduced, and advancement in genomic type techniques enables the identification of novel biomarkers to diagnose diseases.
Imaging type to identify neurological biomarkers is expected to witness fast growth within the market throughout the forecast period. The increasing technological transformations and advancing research and development in neuroscience are compelling surgeons and professionals to use the modern type of techniques to identify biomarkers instead of the conventional types.
Depending on the end-users, the neurological biomarkers market is categorized as hospital laboratories, independent clinical diagnostic centers, research organizations, and others. Among these, hospital laboratories hold the largest share and have their dominance in the market. These hospital laboratories have quick and easy access to neurosurgeons and various other professionals that can efficiently diagnose the disease faster compared to the rest of the end-users. Also, these hospital laboratories being a part of more outstanding medical infrastructure and investment have better and advanced facilities and instruments like biomarkers to identify diseases or disorders.
The independent clinical diagnostic centers are expected to witness fast growth within the market throughout the forecast period because these independent clinics have a greater level of investments from the private entities, with better and advanced techniques to identify the neurological biomarkers.
North America has its dominance and the largest share in the neurological biomarkers market. Countries like the United States are highly research-driven countries, which have contributed tremendously to the development of techniques and measures utilized to identify the neurological biomarkers and the diagnosis of these diseases. The rate of people getting diagnosed with neurological diseases like Alzheimer's, Parkinson's, and autism is enormous in the North American countries, thus accelerating growth in the neurological biomarkers market of the region.
Asia Pacific region is presumed to grow at the fastest rate within the neurological biomarkers market throughout the forecast period. Within their population of 1.27 billion people, a country like India reports approximately 30 million cases of neurological diseases every year. Other countries like China, Japan, Korea, and many other South Asian countries have an emerging ratio of neurological diseases being diagnosed every year. These countries are gradually progressing in their medical sectors, thus adapting to various techniques and processes to identify the neurological biomarkers, thus subsequently improving their efficiency in accurately diagnosing neurological diseases. These countries in the APAC region are also tremendously improving their research and development in the field of neuroscience, and there has been an exponential increase in the number of professionals and neurosurgeons to diagnose and treat these neurological diseases, thus, leading to robust growth in this region.
Acumen Pharmaceuticals, Abbott, Banyan Biomarkers, Inc., Athena Diagnostics, QIAGEN, AbaStar MDx, Inc., Alseres Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and Myriad RBM, Inc. are few prominent competitors in the market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Neurological Biomarkers Industry Overview, 2016-2026
2.1.1 Industry Overview
2.1.2 Application Overview
2.1.3 Type Overview
2.1.4 End-User Overview
2.1.5 Regional Overview
Chapter 3 Neurological Biomarkers Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2016-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Rise in the Incidence of Neurological Disorders
3.3.1.2 Growing Technological Developments
3.3.1.3 Increasing Healthcare Spending
3.3.2 Industry Challenges
3.3.2.1 Absence of Pre-Analytical Tests And Failure To Investigate the Efficiency Of The Biomarker
3.4 Prospective Growth Scenario
3.4.1 Application Growth Scenario
3.4.2 Type Growth Scenario
3.4.3 End-User Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Neurological Biomarkers Market, By Application
4.1 Application Outlook
4.2 Alzheimer’s Disease
4.2.1 Market Size, By Region, 2016-2026 (USD Million)
4.3 Parkinson’s Disease
4.3.1 Market Size, By Region, 2016-2026 (USD Million)
4.4 Multiple Sclerosis
4.4.1 Market Size, By Region, 2016-2026 (USD Million)
4.5 Autism Spectrum Disorders
4.5.1 Market Size, By Region, 2016-2026 (USD Million)
4.6 Others
4.6.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 5 Neurological Biomarkers Market, By Type
5.1 Type Outlook
5.2 Genomic
5.2.1 Market Size, By Region, 2016-2026 (USD Million)
5.3 Proteomic
5.3.1 Market Size, By Region, 2016-2026 (USD Million)
5.4 Metabolomic
5.4.1 Market Size, By Region, 2016-2026 (USD Million)
5.5 Imaging
5.5.1 Market Size, By Region, 2016-2026 (USD Million)
5.6 Others
5.6.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 6 Neurological Biomarkers Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2016-2026 (USD Million)
6.2.2 Market Size, By Application, 2016-2026 (USD Million)
6.2.3 Market Size, By Type, 2016-2026 (USD Million)
6.2.4 Market Size, By End-User, 2016-2026 (USD Million)
6.2.5 U.S.
6.2.5.1 Market Size, By Application, 2016-2026 (USD Million)
6.2.5.2 Market Size, By Type, 2016-2026 (USD Million)
6.2.5.3 Market Size, By End-User, 2016-2026 (USD Million)
6.2.6 Canada
6.2.6.1 Market Size, By Application, 2016-2026 (USD Million)
6.2.6.2 Market Size, By Type, 2016-2026 (USD Million)
6.2.6.2 Market Size, By End-User, 2016-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2016-2026 (USD Million)
6.3.2 Market Size, By Application, 2016-2026 (USD Million)
6.3.3 Market Size, By Type, 2016-2026 (USD Million)
6.3.4 Market Size, By End-User, 2016-2026 (USD Million)
6.3.5 Germany
6.2.5.1 Market Size, By Application, 2016-2026 (USD Million)
6.2.5.2 Market Size, By Type, 2016-2026 (USD Million)
6.2.5.3 Market Size, By End-User, 2016-2026 (USD Million)
6.3.6 UK
6.3.6.1 Market Size, By Application, 2016-2026 (USD Million)
6.3.6.2 Market Size, By Type, 2016-2026 (USD Million)
6.3.6.2 Market Size, By End-User, 2016-2026 (USD Million)
6.3.7 France
6.3.7.1 Market Size, By Application, 2016-2026 (USD Million)
6.3.7.2 Market Size, By Type, 2016-2026 (USD Million)
6.3.7.3 Market Size, By End-User, 2016-2026 (USD Million)
6.3.8 Italy
6.3.8.1 Market Size, By Application, 2016-2026 (USD Million)
6.3.8.2 Market Size, By Type, 2016-2026 (USD Million)
6.3.8.3 Market Size, By End-User, 2016-2026 (USD Million)
6.3.9 Spain
6.3.9.1 Market Size, By Application, 2016-2026 (USD Million)
6.3.9.2 Market Size, By Type, 2016-2026 (USD Million)
6.3.9.2 Market Size, By End-User, 2016-2026 (USD Million)
6.3.10 Russia
6.3.10.1 Market Size, By Application, 2016-2026 (USD Million)
6.3.10.2 Market Size, By Type, 2016-2026 (USD Million)
6.3.10.2 Market Size, By End-User, 2016-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2016-2026 (USD Million)
6.4.2 Market Size, By Application, 2016-2026 (USD Million)
6.4.3 Market Size, By Type, 2016-2026 (USD Million)
6.4.4 Market Size, By End-User, 2016-2026 (USD Million)
6.4.5 China
6.4.5.1 Market Size, By Application, 2016-2026 (USD Million)
6.4.5.2 Market Size, By Type, 2016-2026 (USD Million)
6.4.5.2 Market Size, By End-User, 2016-2026 (USD Million)
6.4.6 India
6.4.6.1 Market Size, By Application, 2016-2026 (USD Million)
6.4.6.2 Market Size, By Type, 2016-2026 (USD Million)
6.4.6.3 Market Size, By End-User, 2016-2026 (USD Million)
6.4.7 Japan
6.4.7.1 Market Size, By Application, 2016-2026 (USD Million)
6.4.7.2 Market Size, By Type, 2016-2026 (USD Million)
6.4.7.3 Market Size, By End-User, 2016-2026 (USD Million)
6.4.8 Australia
6.4.8.1 Market Size, By Application, 2016-2026 (USD Million)
6.4.8.2 Market size, By Type, 2016-2026 (USD Million)
6.4.8.2 Market size, By End-User, 2016-2026 (USD Million)
6.4.9 South Korea
6.4.9.1 Market Size, By Application, 2016-2026 (USD Million)
6.4.9.2 Market Size, By Type, 2016-2026 (USD Million)
6.4.9.2 Market Size, By End-User, 2016-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2016-2026 (USD Million)
6.5.2 Market Size, By Application, 2016-2026 (USD Million)
6.5.3 Market Size, By Type, 2016-2026 (USD Million)
6.5.4 Market Size, By End-User, 2016-2026 (USD Million)
6.5.5 Brazil
6.5.5.1 Market Size, By Application, 2016-2026 (USD Million)
6.5.5.2 Market Size, By Type, 2016-2026 (USD Million)
6.5.5.2 Market Size, By End-User, 2016-2026 (USD Million)
6.5.6 Mexico
6.5.6.1 Market Size, By Application, 2016-2026 (USD Million)
6.5.6.2 Market Size, By Type, 2016-2026 (USD Million)
6.5.6.2 Market Size, By End-User, 2016-2026 (USD Million)
6.5.7 Argentina
6.5.7.1 Market Size, By Application, 2016-2026 (USD Million)
6.5.7.2 Market Size, By Type, 2016-2026 (USD Million)
6.5.7.2 Market Size, By End-User, 2016-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2016-2026 (USD Million)
6.6.2 Market Size, By Application, 2016-2026 (USD Million)
6.6.3 Market Size, By Type, 2016-2026 (USD Million)
6.6.4 Market Size, By End-User, 2016-2026 (USD Million)
6.6.5 Saudi Arabia
6.6.5.1 Market Size, By Application, 2016-2026 (USD Million)
6.6.5.2 Market Size, By Type, 2016-2026 (USD Million)
6.6.5.3 Market Size, By End-User, 2016-2026 (USD Million)
6.6.6 UAE
6.6.6.1 Market Size, By Application, 2016-2026 (USD Million)
6.6.6.2 Market Size, By Type, 2016-2026 (USD Million)
6.6.6.3 Market Size, By End-User, 2016-2026 (USD Million)
6.6.7 South Africa
6.6.7.1 Market Size, By Application, 2016-2026 (USD Million)
6.6.7.2 Market Size, By Type, 2016-2026 (USD Million)
6.6.7.2 Market Size, By End-User, 2016-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Acumen Pharmaceuticals
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Abbott
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Banyan Biomarkers, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 Athena Diagnostics
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 QIAGEN
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 AbaStar MDx, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 Alseres Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Thermo Fisher Scientific Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Bio-Rad Laboratories, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Myriad RBM, Inc.
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
7.12 Other Companies
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info Graphic Analysis
The Global Neurological Biomarkers Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Neurological Biomarkers Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
